Safety and Effectiveness of Zintevir (AR177) Given to HIV-Infected Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if it is safe and effective to give zintevir (AR177) to
asymptomatic (no symptoms) HIV-infected patients.
Zintevir belongs to a new class of anti-HIV drugs, the integrase inhibitors. HIV uses the
protein integrase to infect a cell. Integrase inhibitors block integrase and may stop
replication of HIV.